Completed PHASE2 INTERVENTIONAL 2-arm NCT01171326

Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo

Sponsor: Vyne Therapeutics Inc.

Conditions Impetigo

Interventions Topical Minocycline Foam FXFM244

Updated 7 times since 2017 Last updated: Dec 9, 2013 Started: Aug 31, 2010 Primary completion: Mar 31, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Impetigo and is currently completed. Vyne Therapeutics Inc. leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vyne Therapeutics Inc.

Data source: Vyne Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Netanya, Israel